Hee Kyung Kim, Kyung Hee Park, Youjin Kim, Song Ee Park, Han Sang Lee, Sung Won Lim, Jang Ho Cho, Ji-Yeon Kim, Jeong Eon Lee, Jin Seok Ahn, Young-Hyuck Im, Jong Han Yu, Yeon Hee Park
Cancer Res Treat. 2019;51(2):737-747. Published online September 5, 2018
Purpose
We aimed to analyze the discordance between immunohistochemistry (IHC)-based surrogate subtyping and PAM50 intrinsic subtypes and to assess overall survival (OS) according to discordance.
Materials and Methods
A total of 607 patients were analyzed. Hormone receptor (HR) expression was evaluated by IHC, and human epidermal growth factor receptor 2 (HER2) expression was analyzed by IHC and/or fluorescence in situ hybridization. PAM50 intrinsic subtypes were determined according to 50 cancer genes using the NanoString nCounter Analysis System. We matched concordant tumor as luminal A and HR+/HER2–, luminal B and HR+/HER2+, HR–/HER2+ and HER2–enriched, and triple-negative breast cancer (TNBC) and normal- or basal-like. We used Ion Ampliseq Cancer Panel v2 was used to identify the genomic alteration related with discordance. The Kaplan-Meier method was used to estimate OS.
Results
In total, 233 patients (38.4%) were discordant between IHC-based subtype and PAM50 intrinsic subtype. Using targeted sequencing, we detected somatic mutation–related discordant breast cancer including the VHL gene in the HR+/HER2– group (31% in concordant group, 0% in discordant group, p=0.03) and the IDH and RET genes (7% vs. 12%, p=0.02 and 0% vs. 25%, p=0.02, respectively) in the TNBC group. Among the luminal A/B patients with a discordant result had significantly worse OS (median OS, 73.6 months vs. not reached; p < 0.001), and among the patients with HR positivity, the basal-like group as determined by PAM50 showed significantly inferior OS compared to other intrinsic subtypes (5-year OS rate, 92.2% vs. 75.6%; p=0.01).
Conclusion
A substantial portion of patients showed discrepancy between IHC subtype and PAM50 intrinsic subtype in our study. The survival analysis demonstrated that current IHC-based classification could mislead the treatment and result in poor outcome. Current guidelines for IHC might be updated accordingly.
Citations
Citations to this article as recorded by
Beyond Hormone Receptors: liquid biopsy tools to unveil new clinical meanings and empower therapeutic decision-making in Luminal-like metastatic breast cancer Brenno Pastò, Riccardo Vida, Arianna Dri, Lorenzo Foffano, Serena Della Rossa, Lorenzo Gerratana, Fabio Puglisi The Breast.2025; 79: 103859. CrossRef
Kinome-Focused CRISPR-Cas9 Screens in African Ancestry Patient-Derived Breast Cancer Organoids Identify Essential Kinases and Synergy of EGFR and FGFR1 Inhibition Florencia P. Madorsky Rowdo, Rachel Martini, Sarah E. Ackermann, Colin P. Tang, Marvel Tranquille, Adriana Irizarry, Ilkay Us, Omar Alawa, Jenna E. Moyer, Michael Sigouros, John Nguyen, Majd Al Assaad, Esther Cheng, Paula S. Ginter, Jyothi Manohar, Brian Cancer Research.2025; 85(3): 551. CrossRef
Defining the regulatory logic of breast cancer using single-cell epigenetic and transcriptome profiling Matthew J. Regner, Susana Garcia-Recio, Aatish Thennavan, Kamila Wisniewska, Raul Mendez-Giraldez, Brooke Felsheim, Philip M. Spanheimer, Joel S. Parker, Charles M. Perou, Hector L. Franco Cell Genomics.2025; 5(2): 100765. CrossRef
Evaluation and Comparison of Prognostic Multigene Tests in Early‐Stage Breast Cancer: Which Is the Most Effective? A Literature Review Exploring Clinical Utility to Enhance Therapeutic Management in Luminal Patients Marianna Rita Brogna, Gerardo Ferrara, Valeria Varone, Angela Montone, MariaRosaria Schiano, Michele DelSesto, Francesca Collina Molecular Carcinogenesis.2025;[Epub] CrossRef
Imaging genomics of cancer: a bibliometric analysis and review Xinyi Gou, Aobo Feng, Caizhen Feng, Jin Cheng, Nan Hong Cancer Imaging.2025;[Epub] CrossRef
PAM50 breast cancer subtypes and survival of patients in rural Ethiopia without adjuvant treatment: a prospective observational study Judith Katharina Ballé, Martina Vetter, Tariku Wakuma Kenea, Pia Eber-Schulz, Christian Reibold, Hannes-Viktor Ziegenhorn, Kathrin Stückrath, Claudia Wickenhauser, Adamu Addissie, Pablo Santos, Eva Johanna Kantelhardt, Sefonias Getachew, Marcus Bauer BMC Cancer.2024;[Epub] CrossRef
Migratory Tumor Cells Cooperate with Cancer Associated Fibroblasts in Hormone Receptor-Positive and HER2-Negative Breast Cancer Eun Hye Joo, Sangmin Kim, Donghyun Park, Taeseob Lee, Woong-Yang Park, Kyung Yeon Han, Jeong Eon Lee International Journal of Molecular Sciences.2024; 25(11): 5876. CrossRef
Discovery of a proliferation essential gene signature and actin‐like 6A as potential biomarkers for predicting prognosis and neoadjuvant chemotherapy response in triple‐positive breast cancer Xiaofen Li, Shiping Luo, Wenfen Fu, Mingyao Huang, Xiewei Huang, Shaohong Kang, Jie Zhang, Qingshui Wang, Chuangui Song Cancer.2024; 130(S8): 1435. CrossRef
Breast Cancer Molecular Subtyping in Practice: A Real-World Study of the APIS Breast Cancer Subtyping Assay in a Consecutive Series of Breast Core Biopsies Silvana Di Palma, Panagiotis Koliou, Alex Simonovic, Daniela Costa, Catherine Faulkes, Brenda Kobutungi, Felicity Paterson, Jonathan David Horsnell, Farrokh Pakzad, Tracey Irvine, Polly Partlett, Elizabeth Clayton, Nadine Collins International Journal of Molecular Sciences.2024; 25(5): 2616. CrossRef
iCluF: an unsupervised iterative cluster-fusion method for patient stratification using multiomics data Sushil K Shakyawar, Balasrinivasa R Sajja, Jai Chand Patel, Chittibabu Guda, Marieke Kuijjer Bioinformatics Advances.2024;[Epub] CrossRef
Differences in Histological Subtypes of Invasive Lobular Breast Carcinoma According to Immunohistochemical Molecular Classification Ivan Ilić, Jana Cvetković, Ratko Ilić, Ljubiša Cvetković, Aleksandar Milićević, Stefan Todorović, Pavle Ranđelović Diagnostics.2024; 14(6): 660. CrossRef
Molecular subtyping improves breast cancer diagnosis in the Copenhagen Breast Cancer Genomics Study Tobias Berg, Maj-Britt Jensen, Alan Celik, Maj-Lis Talman, Maria Anna Misiakou, Ann Søegaard Knoop, Finn Cilius Nielsen, Bent Ejlertsen, Maria Rossing JCI Insight.2024;[Epub] CrossRef
Effect of internal subtype on the efficacy of CDK4/6 inhibitor therapy in advanced HR+/HER2breast cancer: A review Katerina S. Grechukhina, Daria A. Filonenko, Margarita V. Sukhova, Liudmila G. Zhukova Journal of Modern Oncology.2024; 26(2): 182. CrossRef
Clinicopathological characteristics, treatment patterns and outcomes in patients with HER2-positive breast cancer based on hormone receptor status: a retrospective study Ran Ran, Shidi Zhao, Yan Zhou, Xinyue Hang, Hui Wang, Yuan Fan, Yusi Zhang, Yifan Qiao, Jin Yang, Danfeng Dong BMC Cancer.2024;[Epub] CrossRef
LUCAT1-Mediated Competing Endogenous RNA (ceRNA) Network in Triple-Negative Breast Cancer Deepak Verma, Sumit Siddharth, Ashutosh S. Yende, Qitong Wu, Dipali Sharma Cells.2024; 13(22): 1918. CrossRef
Systemically Identifying Triple-Negative Breast Cancer Subtype-Specific Prognosis Signatures, Based on Single-Cell RNA-Seq Data Kaiyuan Xing, Bo Zhang, Zixuan Wang, Yanru Zhang, Tengyue Chai, Jingkai Geng, Xuexue Qin, Xi Steven Chen, Xinxin Zhang, Chaohan Xu Cells.2023; 12(3): 367. CrossRef
Moanna: Multi-Omics Autoencoder-Based Neural Network Algorithm for Predicting Breast Cancer Subtypes Richard Lupat, Rashindrie Perera, Sherene Loi, Jason Li IEEE Access.2023; 11: 10912. CrossRef
Discordance between PAM50 intrinsic subtyping and immunohistochemistry in South African women with breast cancer Thérèse Dix-Peek, Boitumelo P. Phakathi, Eunice J. van den Berg, Caroline Dickens, Tanya N. Augustine, Herbert Cubasch, Alfred I. Neugut, Judith S. Jacobson, Maureen Joffe, Paul Ruff, Raquel A. B. Duarte Breast Cancer Research and Treatment.2023; 199(1): 1. CrossRef
A Simple Method for Robust and Accurate Intrinsic Subtyping of Breast Cancer Mehdi Hamaneh, Yi-Kuo Yu Cancer Informatics.2023;[Epub] CrossRef
XAI-MethylMarker: Explainable AI approach for biomarker discovery for breast cancer subtype classification using methylation data Sheetal Rajpal, Ankit Rajpal, Arpita Saggar, Ashok K. Vaid, Virendra Kumar, Manoj Agarwal, Naveen Kumar Expert Systems with Applications.2023; 225: 120130. CrossRef
XAI-CNVMarker: Explainable AI-based copy number variant biomarker discovery for breast cancer subtypes Sheetal Rajpal, Ankit Rajpal, Manoj Agarwal, Virendra Kumar, Ajith Abraham, Divya Khanna, Naveen Kumar Biomedical Signal Processing and Control.2023; 84: 104979. CrossRef
The role of tumor microenvironment in drug resistance: emerging technologies to unravel breast cancer heterogeneity Vincenzo Salemme, Giorgia Centonze, Lidia Avalle, Dora Natalini, Alessio Piccolantonio, Pietro Arina, Alessandro Morellato, Ugo Ala, Daniela Taverna, Emilia Turco, Paola Defilippi Frontiers in Oncology.2023;[Epub] CrossRef
HER2+ Breast Cancer Escalation and De-Escalation Trial Design: Potential Role of Intrinsic Subtyping Coralia Bueno Muiño, Miguel Martín, María del Monte-Millán, José Ángel García-Saénz, Sara López-Tarruella Cancers.2022; 14(3): 512. CrossRef
Association of HER-2/CEP17 Ratio and HER-2 Copy Number With pCR Rate in HER-2-Positive Breast Cancer After Dual-Target Neoadjuvant Therapy With Trastuzumab and Pertuzumab Fanfan Li, Qian Ju, Cong Gao, Jingjing Li, Xiaolei Wang, Min Yan, Liying Zhang, Meiling Huang, Qihe Long, Xiangting Jin, Nanlin Li Frontiers in Oncology.2022;[Epub] CrossRef
Prognostic significance of different molecular typing methods and immune status based on RNA sequencing in HR-positive and HER2-negative early-stage breast cancer Xinyu Ren, Yu Song, Yanna zhang, Huanwen Wu, Longyun Chen, Junyi Pang, Liangrui Zhou, Songjie Shen, Zhiyong Liang BMC Cancer.2022;[Epub] CrossRef
Molecular Subtyping of Invasive Breast Cancer Using a PAM50-Based Multigene Expression Test-Comparison with Molecular-Like Subtyping by Tumor Grade/Immunohistochemistry and Influence on Oncologist’s Decision on Systemic Therapy in a Real-World Setting Ramona Erber, Miriam Angeloni, Robert Stöhr, Michael P. Lux, Daniel Ulbrich-Gebauer, Enrico Pelz, Agnes Bankfalvi, Kurt W. Schmid, Robert F. H. Walter, Martina Vetter, Christoph Thomssen, Doris Mayr, Frederick Klauschen, Peter Sinn, Karl Sotlar, Katharina International Journal of Molecular Sciences.2022; 23(15): 8716. CrossRef
The Current Staging and Classification Systems of Breast Cancer and Their Pitfalls: Is It Possible to Integrate the Complexity of this Neoplasm into a Unified Staging System? Felipe Andrés Cordero da Luz, Breno Jeha Araújo, Rogério Agenor de Araújo Critical Reviews in Oncology/Hematology.2022; : 103781. CrossRef
Prognostic factors and molecular subtypes in young women with breast cancer Yasmin Shukair, Rafaela Veiga Monteiro Mastology.2022;[Epub] CrossRef
Understanding Breast Cancers through Spatial and High-Resolution Visualization Using Imaging Technologies Haruko Takahashi, Daisuke Kawahara, Yutaka Kikuchi Cancers.2022; 14(17): 4080. CrossRef
Risk Stratification for Breast Cancer Patient by Simultaneous Learning of Molecular Subtype and Survival Outcome Using Genetic Algorithm-Based Gene Set Selection Bonil Koo, Dohoon Lee, Sangseon Lee, Inyoung Sung, Sun Kim, Sunho Lee Cancers.2022; 14(17): 4120. CrossRef
Detecting the expression of HRs and BCL2 via IHC can help identify luminal A-like subtypes of triple-positive breast cancers Yingying Xu, Yonghao Liang, Guanghao Yin Clinical and Translational Oncology.2022; 25(4): 1024. CrossRef
Association of Endocrine Therapy for HR+/ERBB2+ Metastatic Breast Cancer With Survival Outcomes Marcela Carausu, Matthieu Carton, Véronique Diéras, Thierry Petit, Séverine Guiu, Anthony Gonçalves, Paule Augereau, Jean Marc Ferrero, Christelle Levy, Mony Ung, Isabelle Desmoulins, Marc Debled, Thomas Bachelot, Barbara Pistilli, Jean-Sébastien Frenel, JAMA Network Open.2022; 5(12): e2247154. CrossRef
Treatment strategies for hormone receptor-positive, human epidermal growth factor receptor 2-positive (HR+/HER2+) metastatic breast cancer: A review Ran Ran, Yingying Ma, Hui Wang, Jin Yang, Jiao Yang Frontiers in Oncology.2022;[Epub] CrossRef
PAM50- and immunohistochemistry-based subtypes of breast cancer and their relationship with breast cancer mortality in a population-based study Lin Wang, Qian Li, Vasily N. Aushev, Alfred I. Neugut, Regina M. Santella, Susan Teitelbaum, Jia Chen Breast Cancer.2021; 28(6): 1235. CrossRef
Triphasic DeepBRCA-A Deep Learning-Based Framework for Identification of Biomarkers for Breast Cancer Stratification Sheetal Rajpal, Manoj Agarwal, Virendra Kumar, Anamika Gupta, Naveen Kumar IEEE Access.2021; 9: 103347. CrossRef
Precision treatment exploration of breast cancer based on heterogeneity analysis of lncRNAs at the single-cell level Yan Zhang, Denan Zhang, Qingkang Meng, Ziqi Liu, Hongbo Xie, Lei Liu, Fei Xu, Xiujie Chen BMC Cancer.2021;[Epub] CrossRef
A single-cell and spatially resolved atlas of human breast cancers Sunny Z. Wu, Ghamdan Al-Eryani, Daniel Lee Roden, Simon Junankar, Kate Harvey, Alma Andersson, Aatish Thennavan, Chenfei Wang, James R. Torpy, Nenad Bartonicek, Taopeng Wang, Ludvig Larsson, Dominik Kaczorowski, Neil I. Weisenfeld, Cedric R. Uytingco, Jen Nature Genetics.2021; 53(9): 1334. CrossRef
Improving Prognosis of Surrogate Assay for Breast Cancer Patients by Absolute Quantitation of Ki67 Protein Levels Using Quantitative Dot Blot (QDB) Method Junmei Hao, Yan Lyu, Jiarui Zou, Yunyun Zhang, Shuishan Xie, Lili Jing, Fangrong Tang, Jiahong Lyu, Wenfeng Zhang, Jianbo Zhang, Xunting Wang, Kuisheng Chen, Jiandi Zhang Frontiers in Oncology.2021;[Epub] CrossRef
Poor histologic tumor response after adjuvant therapy in basal-like HER2-positive breast carcinoma Danhui Zhao, Xin Fu, Joseph Rohr, Yingmei Wang, Mingyang Li, Xiuming Zhang, Junhui Qin, Mengwei Xu, Chao Li, Guorui Sun, Zhe Wang, Shuangping Guo Pathology - Research and Practice.2021; 228: 153677. CrossRef
Moving beyond endocrine therapy for luminal metastatic breast cancer in the precision medicine era: looking for new targets Stefania Morganti, Giuseppe Curigliano Expert Review of Precision Medicine and Drug Development.2020; 5(1): 7. CrossRef
MRPS23 amplification and gene expression in breast cancer; association with proliferation and the non-basal subtypes Elise Klæstad, Signe Opdahl, Monica Jernberg Engstrøm, Borgny Ytterhus, Elisabeth Wik, Anna Mary Bofin, Marit Valla Breast Cancer Research and Treatment.2020; 180(1): 73. CrossRef
Dual HER2 Blockade versus a Single Agent in Trastuzumab-Containing Regimens for HER2-Positive Early Breast Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials Liuwen Yu, Fangmeng Fu, Jing Li, Meng Huang, Bangwei Zeng, Yuxiang Lin, Qian Mei, Jinxing Lv, Chuan Wang Journal of Oncology.2020; 2020: 1. CrossRef
Hormone Receptor-Status Prediction in Breast Cancer Using Gene Expression Profiles and Their Macroscopic Landscape Seokhyun Yoon, Hye Sung Won, Keunsoo Kang, Kexin Qiu, Woong June Park, Yoon Ho Ko Cancers.2020; 12(5): 1165. CrossRef
Do 21-Gene Recurrence Score Influence Chemotherapy Decisions in T1bN0 Breast Cancer Patients? Jing Yu, Jiayi Wu, Ou Huang, Jianrong He, Zhu Li, Weiguo Chen, Yafen Li, Xiaosong Chen, Kunwei Shen Frontiers in Oncology.2020;[Epub] CrossRef
DGM-CM6: A New Model to Predict Distant Recurrence Risk in Operable Endocrine-Responsive Breast Cancer Lei Lei, Xiao-Jia Wang, Yin-Yuan Mo, Skye Hung-Chun Cheng, Yunyun Zhou Frontiers in Oncology.2020;[Epub] CrossRef
Subtype-specific risk models for accurately predicting the prognosis of breast cancer using differentially expressed autophagy-related genes Baoai Han, He Zhang, Yuying Zhu, Xingxing Han, Zhiyong Wang, Zicong Gao, Yue Yuan, Ruinan Tian, Fei Zhang, Ruifang Niu Aging.2020; 12(13): 13318. CrossRef
Clinical implications of HER2 mRNA expression and intrinsic subtype in refractory HER2-positive metastatic breast cancer treated with pan-HER inhibitor, poziotinib Ji-Yeon Kim, Kyunghee Park, Seock-Ah Im, Kyung Hae Jung, Joohyuk Sohn, Keun Seok Lee, Jee Hyun Kim, Yaewon Yang, Yeon Hee Park Breast Cancer Research and Treatment.2020; 184(3): 743. CrossRef
Quantification of Estrogen Receptor, Progesterone Receptor, and Human Epidermal Growth Factor Receptor 2 Protein Expression in Bone Biopsies by Targeted Mass Spectrometry without Acid Decalcification Regine M Schoenherr, Uliana J Voytovich, Jeffrey R Whiteaker, Vijayakrishna K Gadi, Julie R Gralow, Amanda G Paulovich Clinical Chemistry.2020; 66(11): 1459. CrossRef
A Topic Modeling Analysis of TCGA Breast and Lung Cancer Transcriptomic Data Filippo Valle, Matteo Osella, Michele Caselle Cancers.2020; 12(12): 3799. CrossRef
Treatment selection for patients with equivocal HER2 status and in luminal versus HER2-enriched disease Giuseppe Viale, Elisabetta Munzone The Breast.2019; 48: S49. CrossRef